Inquiry on the latest medical insurance price of Bezotevan in 2025

Belzutifan (Belzutifan) is a new oral inhibitor targeting HIF-2α (hypoxia-inducible factor-2α). It is one of the few targeted drugs approved in the world for the treatment of VHL syndrome-related solid tumors. It was developed by Merck & Co. in the United States, with the trade name Welireg. It was approved for marketing by the U.S. FDA for the first time in 2021, becoming the first HIF-2α inhibitor approved for VHL syndrome-related tumors. In China, besotivan has also completed registration approval and been officially launched in 2024.

The main indications for bezutivan includeVHL (von Hippel-Lindau) disease-related focal renal cell carcinoma (RCC) , central nervous system hemangioblastoma (including retinal lesions) and pancreatic neuroendocrine tumors. Most of these diseases are part of hereditary tumor syndromes. Patients often develop multiple tumor lesions at a young age, and traditional treatments such as surgery, radiotherapy, chemotherapy or immunotherapy have limited effect. By specifically inhibiting HIF-2α, Bestifan effectively breaks the adaptation mechanism of cancer cells to a hypoxic environment, thereby inhibiting tumor growth. It is highly targeted and well tolerated, making it an important treatment option for VHL patients.

As for its domestic medical insurance prices, there is currently no official channel to announce detailed reimbursement information. Since this drug is an innovative drug that has only been introduced into the Chinese market in the past two years, it is still in the review stage for medical insurance access. Based on previous cycles of similar innovative targeted drugs being included in the medical insurance, it is estimated that bezotivan is likely to be included in the new version of the National Medical Insurance Catalog within the next 1 to 2 years. At this stage, the market retail price of the drug has not yet been fully disclosed, but as an imported original targeted drug, its price is expected to be relatively high. Referring to the pricing situation in overseas markets, the price of each box may be more than 100,000 yuan, which is very expensive.

Reference materials:https://www.welireg.com/